Search 

Adare Pharmaceutical Technologies (PT) is the specialty CDMO business unit of Adare, a global specialty pharmaceutical company. A science-driven provider of dosage form solutions for the healthcare industry – with expertise in taste masking and customized drug release – Adare PT is a leading partner to pharmaceutical companies across branded, specialty, 505b2, generic and OTC segments. With over 30 years of proven legacy, Adare PT focuses on oral dosage forms for small molecules across all therapeutic areas. To learn more, email us at BusDevROW@adarepharma.com.

Alfasigma is an Italian pharmaceutical company set up in May 2015 as result of an industrial partnership between two important pharma groups in Italy, Alfa Wassermann and Sigma-Tau. Alfasigma is ranked among the top five players in the pharmaceutical sector in Italy both in terms of Rx and OTC products with a total consolidated turnover of 1,1 billion Euro in 2017 and an headcount of 2.800 employees. Outside Italy, the new company operates directly in 16 countries among which USA, China, Russia, India and most European countries. Alfasigma has a wide range of products on the market in the following therapeutic areas: Gastrointestinal, Vascular, Muscoskeletal/Rheumathology, Cardiovascular, Metabolic, Respiratory. Alfasigma is also focused on research and development, including biotechnological research. Alongside R&D, also Manufacturing is a field where Alfasigma is strongly active with three production plants in Italy out of which the Alanno's plant operating as CMO.

Angelini, established in 1919, is a privately-held, family owned international Group with a consolidated revenue for 2017 of € 1,7 billion. Pharma represents the core business of Angelini family, with a revenue of € 851 million.

Headquartered in Rome, Italy, Angelini Pharma is a fully integrated company from R&D to Commercial and operates directly in more than twenty countries, including Italy, Spain, Central Eastern European countries, Russia and Turkey.

Angelini focuses his research and commercial activities mainly on Pain, Infectious Diseases and Central Nervous System.

R&D Department has full development capabilities from discovery to clinical and it has currently development programs ongoing in all the core therapeutic areas. Amongst others, R&D synthetized and developed both Benzydamine- for treatment of Sore throat- and Trazodone- for treatment of Major Depression- two molecules worldwide present either through Angelini direct operations or licensing-out deals.

Angelini field force- that counts more than 1.100 professionals - promotes a wide range of products coming both from internal development and licensing agreements, targeting and detailing a number of Healthcare professionals ranging from Pharmacist and General Practitioner to specialty care physicians of Psychiatry, Neurology, Infectious Disease, Pain, Oncology, Paediatric and Gynaecology.

Angelini represents a partner of choice for new product licenses for its territories with ready-to-use capabilities in terms of Regulatory, Market Access, Medical and Commercial. A list of partners of Angelini includes amongst others Helsinn, Incyte, Allergan, Dainippon Sunovion, Gilead, Zambon, Fidia, Almirall and Expanscience. Business Development is looking for innovative products in late stage development in Pain, Infectious Disease and CNS with companies interested in long-term partnership. M&A and Divestment opportunities are also in the scope when there’s a fitting to Angelini focus and Geography.

BMG Pharma is involved in the development of new healthcare products in the areas of oral care, dermatology including aesthetics, anaemia, osteoarthritis & cancer supportive care.

The company has created a strong portfolio of intellectual property which it has developed into a number of products that have been partnered with companies around the world.

The company recently merged with Sigea,an Italian company with expertise in targeted functional ingredients development currently focused on modified sodium hyaluronate for application in a number of therapeutic areas including dermatology and oral care. This merger will allow BMG to accelerate the development of a number of new products to complement its portfolio.

Fidia Pharma is a dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to over 100 markets around the world through its Subsidiaries and Strategic Partners.

We are the leading company in Italy & Middle East in Osteoarthritis, Pain management, Wound Care and Ophthalmology, and in line with our Fidia Pharma 2025 mission, we're aiming to continue our growth'strend in Europe.

To accomplish that, we are looking for long-term Strategic Partners to distribute and promote our product portfolio in Advanced Wound Care management, Women Health and Ophthalmology.

We offer:

Joint Care portfolio:

- proprietary Hyaluronic Acid based injectable solution (1,3 and 5 injections) for OsteoArthritis;

- newly developed Food Supplements (Cartijoint®) for the protection of articular cartilage;

Ophthalmics:

- Large offer of recently taken over n°2 Italian Ophthalmics company. Products are mainly based on

Hyaluronic Acid and Liposomes and have Dry Eye, Evaporative and Trauma indications. Licensing rights worldwide available for discussion.

Pain & Advanced Wound Care Management:

- Itami®: proprietary Diclofenac Sodium salt patches, creams (Itami Trauma Plus®) and foams (Itamidol ®) for the local treatment of painful and inflammatory pathologies of rheumatic or traumatic origin of the joints, muscles, tendons and ligaments.

- Hyalo4® Family: Hyalo4 Start®, Hyalo4 Control®, Hyalo4 Skin®, Hyalo4 Plus®. Proprietary Hyaluronic Acid Salt based solutions for a wide range of chronic and traumatic wounds.

Women HealthCare:

- proprietary anti-vaginal dryness gel, Hyalofemme®, with clinically proven efficacy.

Aesthetics:

- IAL-SYSTEM®, thanks to the visco-elastic and hydrating properties of hyaluronic acid, is indicated for

cutaneous rejuvenation, since, besides providing medium-lasting correction of cutaneous deficiencies, it

increases the turgidity and the elasticity of the skin.

IAL-SYSTEM ACP® is indicated for a medium lasting corrective action on minor soft tissue defects such as

facial fine lines. It improves skin turgidity and elasticity, giving a rejuvenating effect to the skin.

IAL-SYSTEM DUO® is indicated for long-term correction of medium and deeper skin imperfections, such as horizontal forehead wrinkles and lines around the nose and mouth, as well as to restore volume to lips and other parts of the face. Besides the filling effect, IAL-SYSTEM DUO® improves skin firmness and elasticity, making it look younger.

IAL-SYSTEM® LIPSTICK is indicated for local management of damaged, cracked, and dry lips, even as a result of drug treatments. It can also be used for management of stressed and dry lips following aesthetic treatments with dermal fillers.

We are interested in:

Identifying long term Partners to out-license our product portfolio in Advanced Wound Care management, Women Health, Pain management and Ophthalmology.

We are NOT interested in:

IN Licensing products

Founded in 1985 in Brembate (Bergamo, Italy)as a laboratory for the study of fluid bed granulation technology and its applications
for the pharmaceutical and nutraceutical industry, Fine Foods & Pharmaceuticals N.T.M. continued as a contract manufacturer for oral solid forms dedicated for the pharmaceutical and nutraceutical markets.
FineFoods develops and manufactures formulations in all solid oral forms (powder, granules,tablets film-coated or not, hard-gel capsules) and virtually in every kind of packaging: sachets,sticks, bags, bottles, blisters, jars, tubes and strips.

today, fine foods ntm is one of the biggest independent italian contract manufacturer for nutraceuticals and an increasingly important player in the pharmaceutical market, with more than 450 employees, more than 200 customers and a global turnover close to 110 million € and 3 production plants.

We offer:

- contract manufacturing of pharmaceuticals, nutraceuticals and medical devices;
- license out of our ctd's and formulations; cross-license of ctd's; in-license of ctd in order to manufacture in our plants;
- update of old dossiers to ctd format as well as commissioning of clinical studies all with the purpose to manufacture finished products;
- collaboration and partnership with development companies;
- collaboration and partnership with api producers/traders who develop ctd's;
- contract manufacturing (pharmaceuticals, nutraceuticals, medical devices);
- back-up contract manufacturing (pharmaceuticals, nutraceuticals, medical devices);
- (co)development of formulations (pharmaceuticals, nutraceuticals, medical devices)

I’m looking for…….

We are interested in:

- collaboration and partnership with development companies;
- collaboration and partnership with API producers/traders who develop CTD's;
- contract manufacturing (pharmaceuticals, nutraceuticals, Medical Devices);
- back-up contract manufacturing (pharmaceuticals, nutraceuticals, Medical Devices);
- (co)development of formulations (pharmaceuticals, nutraceuticals, Medical Devices)

We are NOT interested in:

- oncologics;
- biotechnology;
- betalactams and, in general, antibiotics;
- liquids (sterile/non sterile);
- production of clinical batches if not part of a complete development project